HighTower Advisors
KYNB

HighTower Advisors’s Kyntra Bio KYNB Stock Holding History

HighTower Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Buy
39,746
+2
+0% +$14 ﹤0.01% 3217
2026
Q1 		$269K Sell
39,744
-2
-0% -$16 ﹤0.01% 3258
2025
Q4 		$349K Hold
39,746
– – ﹤0.01% 2923
2025
Q3 		$487K Hold
39,746
– – ﹤0.01% 2646
2025
Q2 		$211K Buy
39,746
+23,566
+146% +$172K ﹤0.01% 3233
2025
Q1 		$125K Buy
16,180
+12,060
+293% +$145K ﹤0.01% 3315
2024
Q4 		$54.5K Hold
4,120
– – ﹤0.01% 3449
2024
Q3 		$41K Hold
4,120
– – ﹤0.01% 3430
2024
Q2 		$91K Buy
4,120
+332
+9% +$10.3K ﹤0.01% 3224
2024
Q1 		$222K Sell
3,788
-5,713
-60% -$246K ﹤0.01% 2926
2023
Q4 		$210K Buy
9,501
+5,713
+151% +$86.2K ﹤0.01% 2972
2023
Q3 		$81K Sell
3,788
-12
-0.3% -$471 ﹤0.01% 3145
2023
Q2 		$256K Buy
3,800
+359
+10% +$148K ﹤0.01% 2671
2023
Q1 		$1.6M Hold
3,441
– – ﹤0.01% 1419
2022
Q4 		$1.38M Hold
3,441
– – ﹤0.01% 1494
2022
Q3 		$1.12M Hold
3,441
– – ﹤0.01% 1546
2022
Q2 		$908K Buy
3,441
+188
+6% +$48K ﹤0.01% 1700
2022
Q1 		$977K Hold
3,253
– – ﹤0.01% 1773
2021
Q4 		$1.15M Buy
3,253
+20
+0.6% +$6.23K ﹤0.01% 1699
2021
Q3 		$826K Sell
3,233
-2
-0.1% -$709 ﹤0.01% 1766
2021
Q2 		$2.15M Buy
3,235
+153
+5% +$88.1K 0.01% 1184
2021
Q1 		$2.67M Buy
3,082
+236
+8% +$251K 0.01% 990
2020
Q4 		$2.64M Buy
2,846
+40
+1% +$42K 0.01% 794
2020
Q3 		$2.88M Buy
2,806
+240
+9% +$258K 0.01% 742
2020
Q2 		$2.6M Buy
2,566
+183
+8% +$170K 0.01% 711
2020
Q1 		$2.07M Buy
2,383
+708
+42% +$704K 0.01% 741
2019
Q4 		$1.79M Sell
1,675
-40
-2% -$40.8K 0.01% 897
2019
Q3 		$1.58M Sell
1,715
-7
-0.4% -$7.69K 0.01% 971
2019
Q2 		$1.95M Buy
1,722
+694
+68% +$760K 0.01% 909
2019
Q1 		$1.4M Sell
1,028
-67
-6% -$90.9K 0.01% 996
2018
Q4 		$1.27M Buy
+1,095
New +$1.23M 0.01% 940

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HighTower Advisors's KYNB Position: Q2 2026 in Review

HighTower Advisors increased its Kyntra Bio (KYNB) stake by 0.01% in Q2 2026, buying an estimated $14 and bringing the position to 39,746 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #3217.

HighTower Advisors first reported a position in KYNB in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.88M in Q3 2020. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • HighTower Advisors held 39,746 shares of Kyntra Bio worth $300K as of Q2 2026.
  • HighTower Advisors bought 2 Kyntra Bio shares in Q2 2026, an estimated $14.
  • Kyntra Bio made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3217 holding.
  • HighTower Advisors first reported a position in Kyntra Bio in Q4 2018 and has held it in 31 quarters since.
  • HighTower Advisors's Kyntra Bio position peaked at $2.88M in Q3 2020.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.